M Valeria Bahamondes1, Sara Castro1, Nadia M Marchi1, Michele Marcovici1, Liliana A L A Andrade2, Arlete Fernandes1, Luis Bahamondes3. 1. Human Reproduction Unit, Department of Obstetrics and Gynecology, School of Medical Sciences, University of Campinas, and National Institute of Hormones and Women's Health, Campinas, SP, Brazil. 2. Department of Pathology, School of Medical Sciences, University of Campinas, Campinas, SP, Brazil. 3. Human Reproduction Unit, Department of Obstetrics and Gynecology, School of Medical Sciences, University of Campinas, and National Institute of Hormones and Women's Health, Campinas, SP, Brazil. Electronic address: bahamond@caism.unicamp.br.
Abstract
OBJECTIVES: Apparently, depot-medroxyprogesterone acetate (DMPA) increases a woman's risk of acquiring HIV. The objective of this study was to test whether the vaginal mucosal thickness and Langerhans cell counts were significantly different in long-term DMPA users compared with women users of an intrauterine device (IUD) who had never used DMPA. STUDY DESIGN: Cross-sectional study. Twenty-three DMPA users were matched with 23 nonusers controlled for age, body mass index (BMI; kg/m²), and duration of contraceptive use. Four groups of women were evaluated according to the duration of DMPA use: >1, <5; ≥5, <10; ≥10, <15 or ≥15 years. Estradiol (E₂) levels were compared between the two groups. Histologic sections of vaginal mucosal biopsies were evaluated to measure the mean epithelial thickness and S100 immunostained sections were used to count the number of Langerhans cells/mm. RESULTS: Mean (±S.D.) E₂ levels were significantly lower in DMPA users (39.4±26.6 pg/mL) compared with nonusers (102.6±60.3 pg/mL) despite similar ages (42.3±7.4 and 42.4±7.4 years, respectively). Mean (±S.D.) vaginal thickness was 232.6±108.1 and 229.7±112.9 in DMPA users and nonusers, respectively. There were no differences in vaginal thickness or Langerhans cell count/mm between users and nonusers even after controlling for DMPA duration of use. CONCLUSIONS: Vaginal epithelial thinning or Langerhans cell count was not different between long-term DMPA users and copper-IUD users who had never used DMPA. IMPLICATIONS: No differences were found in vaginal epithelial thickness or in Langerhans cell count between long-term users of the injectable contraceptive DMPA and nonusers.
OBJECTIVES: Apparently, depot-medroxyprogesterone acetate (DMPA) increases a woman's risk of acquiring HIV. The objective of this study was to test whether the vaginal mucosal thickness and Langerhans cell counts were significantly different in long-term DMPA users compared with women users of an intrauterine device (IUD) who had never used DMPA. STUDY DESIGN: Cross-sectional study. Twenty-three DMPA users were matched with 23 nonusers controlled for age, body mass index (BMI; kg/m²), and duration of contraceptive use. Four groups of women were evaluated according to the duration of DMPA use: >1, <5; ≥5, <10; ≥10, <15 or ≥15 years. Estradiol (E₂) levels were compared between the two groups. Histologic sections of vaginal mucosal biopsies were evaluated to measure the mean epithelial thickness and S100 immunostained sections were used to count the number of Langerhans cells/mm. RESULTS: Mean (±S.D.) E₂ levels were significantly lower in DMPA users (39.4±26.6 pg/mL) compared with nonusers (102.6±60.3 pg/mL) despite similar ages (42.3±7.4 and 42.4±7.4 years, respectively). Mean (±S.D.) vaginal thickness was 232.6±108.1 and 229.7±112.9 in DMPA users and nonusers, respectively. There were no differences in vaginal thickness or Langerhans cell count/mm between users and nonusers even after controlling for DMPA duration of use. CONCLUSIONS: Vaginal epithelial thinning or Langerhans cell count was not different between long-term DMPA users and copper-IUD users who had never used DMPA. IMPLICATIONS: No differences were found in vaginal epithelial thickness or in Langerhans cell count between long-term users of the injectable contraceptive DMPA and nonusers.
Authors: Lisa B Haddad; Chelsea B Polis; Anandi N Sheth; Jennifer Brown; Athena P Kourtis; Caroline King; Rana Chakraborty; Igho Ofotokun Journal: Curr HIV/AIDS Rep Date: 2014-12 Impact factor: 5.071
Authors: Katherine G Michel; Richard P H Huijbregts; Jonathan L Gleason; Holly E Richter; Zdenek Hel Journal: J Acquir Immune Defic Syndr Date: 2015-04-15 Impact factor: 3.731
Authors: Irina A Zalenskaya; Neelima Chandra; Nazita Yousefieh; Xi Fang; Oluwatosin E Adedipe; Suzanne S Jackson; Sharon M Anderson; Christine K Mauck; Jill L Schwartz; Andrea R Thurman; Gustavo F Doncel Journal: J Clin Invest Date: 2018-09-17 Impact factor: 14.808
Authors: Halley E M Riley; Petrus S Steyn; Sharon L Achilles; Emily Bass; Andrew L Gray; Chelsea B Polis; James N Kiarie Journal: Contraception Date: 2017-06-07 Impact factor: 3.375
Authors: Kenzie D Birse; Laura M Romas; Brandon L Guthrie; Peter Nilsson; Rose Bosire; James Kiarie; Carey Farquhar; Kristina Broliden; Adam D Burgener Journal: J Infect Dis Date: 2017-02-15 Impact factor: 5.226
Authors: Ann M Carias; Shannon A Allen; Angela J Fought; Katarina Kotnik Halavaty; Meegan R Anderson; Maria L Jimenez; Michael D McRaven; Casey J Gioia; Tara R Henning; Ellen N Kersh; James M Smith; Lara E Pereira; Katherine Butler; S Janet M McNicholl; R Michael Hendry; Patrick F Kiser; Ronald S Veazey; Thomas J Hope Journal: PLoS Pathog Date: 2016-09-22 Impact factor: 6.823